Cytarine 500 is a prescription medication that contains 500mg of Cytarabine, a cytosine arabinoside, a nucleoside analog used in the treatment of various types of cancer, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and lymphoma. It is available in injectable form.
Composition:
Cytarine 500 contains 500mg of Cytarabine, a white or off-white powder.
Mechanism of Action:
Cytarabine works by:
- Inhibiting the synthesis of DNA and RNA
- Preventing the growth and multiplication of cancer cells
- Inducing apoptosis (cell death) in cancer cells
Indication:
Cytarine 500 is indicated for:
- Treatment of acute myeloid leukemia (AML)
- Treatment of acute lymphoblastic leukemia (ALL)
- Treatment of lymphoma, including lymphoblastic lymphoma, Burkitt lymphoma, and non-Hodgkin lymphoma
- Palliative care for patients with cancer who are not responding to other treatments
Dosage:
The recommended dosage of Cytarine 500 is:
- 500mg/m² intravenously every 12 hours for 5-7 days, repeated every 4-6 weeks
- Dose adjustments may be necessary based on patient response and toxicity
Side Effects:
Common side effects of Cytarine 500 may include:
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Hair loss
- Increased risk of infections
- Hematological toxicity (anemia, neutropenia, thrombocytopenia)
- Gastrointestinal toxicity (stomatitis, esophagitis)
- Cardiac toxicity (cardiomyopathy, arrhythmias)
Recommendation:
Cytarine 500 should only be used under the guidance of a healthcare provider. Patients receiving Cytarine 500 treatment should be closely monitored for side effects and potential complications.
Important Note:
- Cytarine 500 is a potent medication that can cause serious side effects, including hematological toxicity and cardiac toxicity. Patients should be closely monitored for these side effects.
- Patients with a history of severe allergic reactions to cytarabine or other nucleoside analogs should not receive Cytarine 500.
- Patients with a history of severe kidney disease or severe liver disease should be closely monitored while receiving Cytarine 500.
Special Precautions:
- Patients with a history of severe neurological disorders should be closely monitored while receiving Cytarine 500.
- Patients with a history of bone marrow suppression or other bone marrow disorders should be closely monitored while receiving Cytarine 500.
It is important to note that the dosage and administration of Cytarine 500 may vary depending on the patient’s individual needs and medical history. It is recommended that patients consult their healthcare provider before taking this medication.
Reviews
There are no reviews yet.